Specialty Pharmacy

PHOENIX — Drug makers Johnson & Johnson and Pharmacyclics have added Avella Specialty Pharmacy to their limited-distribution network for a newly approved blood cancer drug.

Avella said Thursday that it had joined the limited-distribution network for Imbruvica (ibrutinib), which the Food and Drug Administration approved this week for mantle cell lymphoma. Avella is one of five specialty pharmacies to join the network, the company said.

FLINT, Mich. — Diplomat has joined the limited distribution network for a rare form of blood cancer drug marketed by Johnson & Johnson and Pharmacyclics.

The specialty pharmacy said Thursday that J&J subsidiary Janssen Biotech and Pharmacyclics had added it to the limited distribution network for Imbruvica (ibrutinib), which the Food and Drug Administration approved this week for mantle cell lymphoma.

WASHINGTON — The chairman of the Senate Health, Education, Labor and Pensions Committee highlighted the human tragedy wrought by last year's fungal meningitis outbreak linked to contaminated injectable steroids as he spoke in favor of a new law that would regulate compounding pharmacies and implement federal track-and-trace policies for drugs during a recent speech.

SAN DIEGO — The Food and Drug Administration has given special designation to a drug under development by Mast Therapeutics for a rare disease that restricts the flow of blood to the limbs.

NEW YORK — Johnson & Johnson and Pharmacyclics have added a New York-based specialty pharmacy company focused on cancer to their limited-distribution network for a drug recently approved for a rare form of blood cancer.

Onco360 said Wednesday that it had become part of the network for distributing Imbruvica (ibrutinib) capsules. The announcement came the same day that the Food and Drug Adminsitration announced the approval of Imbruvica (ibrutinib) for mantle cell lymphoma, or MCL.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a rare and aggressive type of blood cancer, the agency said Wednesday.

The FDA announced the approval of Imbruvica (ibrutinib), marketed by Pharmacyclics and Johnson & Johnson, for treating mantle cell lymphoma, or MCL. MCL is a rare form of non-Hodgkin lymphoma and represents about 6% of all non-Hodgkin lymphoma cases in the United States. Millennium Pharmaceuticals' Velcade (bortezomib) and Celgene's Revlimid (lenalidomide) are also approved for treating MCL.

LAKE FOREST, Ill. — Hospira had sales of $1 billion in third quarter 2013, the generic drug maker said.

Hospira, which specializes in making generic injectable drugs, as well as biosimilars for the European market, said the sales figures for the quarter were a 1.4% increase over the $994 million in sales reported in third quarter 2012. Profits for the quarter were $84.5 billion, compared with $78.4 billion during the same period last year.

ALEXANDRIA, Va. — The Specialty Pharmacy Certification Board has certified nearly 50 pharmacists following the first round of exams, the group said Monday.

The SPCB announced that 49 pharmacists had earned the Certified Specialty Pharmacist accreditation after taking the exams, which were administered in October, covering intake, fulfillment, clinical management and outcomes.